Iovance Biotherapeutics, Inc. (IOVA)
Summary
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy
Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates
Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
Iovance Biotherapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 789 | $3,856.76 | $3,424.26 | -$432.5 | -11.21% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 54,426 | $226,410 | $345,060.84 | $118,650.84 | 52.41% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 55 | $193.05 | $356.95 | $163.9 | 84.9% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2,115 | $8,822.95 | $13,409.1 | $4,586.15 | 51.98% |
| BG Bart Gancher Intech Investment Management LLC | 109,421 | $514,998.74 | $693,729.14 | $178,730.4 | 34.71% |
Iovance Biotherapeutics, Inc. (IOVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Iovance Biotherapeutics, Inc. ever had a stock split?
Iovance Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Frederick G. Vogt CEO | NASDAQ (NMS) Exchange | 462260100 CUSIP |
| US Country | 975 Employees | - Last Dividend | 26 Sep 2013 Last Split | 15 Oct 2010 IPO Date |
Overview
Iovance Biotherapeutics, Inc. stands as a commercial-stage biotechnology entity dedicated to developing and commercializing innovative cell therapies. Utilizing autologous tumor infiltrating lymphocyte technology, the company aims to provide treatments for metastatic melanoma alongside other solid tumor cancers within the United States. Originating in 2007 and originally known as Lion Biotechnologies, Inc., the company transitioned to its current name in June 2017. With its headquarters in San Carlos, California, Iovance Biotherapeutics has established numerous strategic collaborations and licensing agreements with prominent institutions and companies across the healthcare and biotechnology sectors. These partnerships extend to WuXi Advanced Therapies, Inc.; National Institutes of Health; National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH, aiming to enhance its offering and impact in cancer treatment.
Products and Services
- Amtagvi
Described as a pioneering tumor-derived autologous T cell immunotherapy, Amtagvi is specifically designed for adult patients struggling with unresectable or metastatic melanoma. This product marks Iovance's commitment to offering advanced therapeutic options that leverage the body's immune system to fight cancer.
- Proleukin
An interleukin-2 product, Proleukin serves as a treatment solution for patients with metastatic renal cell carcinoma. Through boosting the patient's immune response, it aims at attacking and eliminating cancer cells, underscoring the company's expertise in immunotherapy.
- Lifileucel in combination with pembrolizumab
This development focuses on treating frontline advanced melanoma patients by combining lifileucel with pembrolizumab. The strategic integration of these treatments exemplifies Iovance's innovative approach towards providing comprehensive care for melanoma patients.
- LN-145
Targeted at addressing the challenges in non-small cell lung cancer (NSCLC) and other solid tumor cancers, LN-145 is an ongoing project that aims to expand the therapeutic reach of the company’s immunotherapy solutions.
- IOV-4001
Currently in Phase 1/2 IOV-GM1-201 clinical trial, IOV-4001 represents Iovance's commitment to innovating treatment options for NSCLC. This exploration into new therapies highlights the company’s dedication to contributing significant advancements in cancer treatment.
- Lifileucel for Gynecological Cancers
Another pivotal area of development, the application of lifileucel for treating gynecological cancers, signifies Iovance's broader endeavor to tackle a variety of cancer types with its cell therapy technologies.
